Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
BIAFW
BIOAFFINITY TECHNOLOGIES, INC.
NASDAQ
$0.30
▲ UP 30.13% (0.07)

KEY STATISTICS

Market Cap$10.69 M
52w High$0.47
52w Low$0.20
Dividend Yield—
Frequency—
P/E1.14
Volume3.20K
Shares Out.4.53M

COMPANY

LEADERSHIP

Maria Zannes
CHIEF EXECUTIVE
Maria Zannes

COMPENSATION 2026

Salary$330,000
Stock Awards$65,989
Incentive Plan Pay$30,000
All Other Comp.$8,994
Total$434,983

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 6, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
57

UPCOMING EARNINGS

DateNov 18, 2026
DayWednesday
Rev. Est.$1.91M
NOV
18
WED

PRICE

$0.30 ▲ UP 30.13% (+$0.07)
$0.20$0.24$0.28$0.3210:02 AM10:59 AM11:57 AM12:54 PM1:51 PM2:49 PM3:46 PM0.30

About bioAffinity Technologies, Inc.

https://www.bioaffinitytech.com ↗

bioAffinity Technologies, Inc. develops non-invasive diagnostic tests and targeted therapeutics for early-stage cancer detection and treatment, using proprietary technology that selectively targets cancer cells.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT BIOAFFINITY TECHNOLOGIES, INC. IS KNOWN FOR

CyPath® Lung
CyPath® Lung

CyPath® Lung is a noninvasive diagnostic test that uses flow cytometry and AI to detect early-stage lung cancer in high-risk individuals by analyzing sputum samples.

COMPETITORS

COMPETITOR
BDSX COMPARE
GH COMPARE
VCYT COMPARE

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR:
Oppenheimer John J.
— · —
2025-08-12
★
DIRECTOR
Rios Roberto
— · —
2025-08-12

SECTORS PEERS

PEERPRICE
ECOR$11.68COMPARE
PRPO$26.46COMPARE
VERU$2.41COMPARE
STRR$9.84COMPARE
CCEL$4.40COMPARE
RMTI$8.06COMPARE
YI$3.60COMPARE
NMTC$1.39COMPARE